Amylx Pharmaceuticals Inc vs Autozone Inc — how do they compare? Amylx Pharmaceuticals Inc trades at $23.65 (market cap $2.53B), while Autozone Inc trades at $3,025.08 (market cap $50.09B). The key difference: Autozone Inc is far larger — about 19.8× Amylx Pharmaceuticals Inc's market cap, and Autozone Inc is trading nearer its 52-week high, Amylx Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| AMLX | AZO | |
|---|---|---|
Market Cap | $2.53B | $50.09B |
Sector | Health | Consumer Cyclical |
52-Week High | $24.19 | $4.35K |
52-Week Low | $7.82 | $2.92K |
Enterprise Value | $2.28B | $62.46B |
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $22.82, down 5.66% on the day, with a bullish technical signal from moving averages and key support at $22. The company reported a net loss of -$144.74M for 2025, with negative ROE and ROA, but holds a $250.8M cash runway into 2028. The pivotal Phase 3 LUCIDITY trial for avexitide is set for a late August/early September 2026 readout, a key near-term catalyst.
Analyst consensus is strongly bullish with a $30.00 price target, though recent earnings misses and negative cash flow from operations in 2026 pose risks. The stock's outlook hinges on successful clinical trial results and the subsequent regulatory pathway for its lead endocrine asset.
AutoZone (AZO) trades at $3,127.29, up 1.88% recently, with a bullish technical signal and strong analyst support. Revenue grew to $18.94B in 2025, though net income margin dipped to 13.19%. The company maintains robust cash flow from operations and recently authorized a $1.5B stock buyback, signaling confidence. Key resistance lies near $3,160, with support at $3,063.
Outlook remains positive with 73% analyst buy ratings and a $3,730 consensus price target, implying ~19% upside. Risks include margin pressure from rising costs and competitive threats. Earnings beats in recent quarters support growth, but investors should monitor execution on international expansion and capex efficiency.
Trailing returns across standard periods
Latest headlines on both assets
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →AutoZone is the premier seller of aftermarket automotive parts, tools, and accessories to do-it-yourself customers in the United States. The company derives an increasing proportion of its sales from domestic commercial customers, although its presence in its home market is still dominated by its do-it-yourself operation, which accounts for nearly 75% of sales in country. AutoZone also has a growing presence in Mexico and Brazil. AutoZone had 6,767 stores in the U.S. (6,051), Mexico (664), and Brazil (52) as of the end of fiscal 2021.
Read more on AZO →